logo
logo
IDXX stock ticker logo

IDEXX Laboratories, Inc.

NASDAQ•IDXX
CEO: Mr. Jonathan J. Mazelsky
Sector: Healthcare
Industry: Medical - Diagnostics & Research
Listing Date: 1991-06-21
IDEXX Laboratories, Inc. develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy. It also provides point-of-care veterinary diagnostic products, including instruments, consumables, and rapid assay test kits; veterinary reference laboratory diagnostic and consulting services; practice management and diagnostic imaging systems and services for veterinarians; and health monitoring, biological materials testing, and laboratory diagnostic instruments, and services for biomedical research community. In addition, the company offers diagnostic and health-monitoring products for livestock, poultry, and dairy; products that test water for various microbiological contaminants; point-of-care electrolytes and blood gas analyzers; in-clinic chemistry, blood and urine chemistry, hematology, immunoassay, urinalysis, and coagulation analyzers; and SNAP rapid assays test kits. Further, it provides Colilert, Colilert-18, and Colisure tests, which detect the presence of total coliforms and E. coli in water; Enterolert, Pseudalert, Filta-Max and Filta-Max xpress, Legiolert, and Quanti-Tray products; and veterinary software and services for independent veterinary clinics and corporate groups. Additionally, the company offers human medical point-of-care products and laboratory diagnostics services. The company markets its products through marketing, customer service, sales, and technical service groups, as well as through independent distributors and other resellers. IDEXX Laboratories, Inc. was incorporated in 1983 and is headquartered in Westbrook, Maine.
Contact Information
One IDEXX Drive, Westbrook, ME, 04092, United States
207-556-0300
www.idexx.com
Market Cap
$45.61B
P/E (TTM)
43.2
26.5
Dividend Yield
--
52W High
$769.98
52W Low
$356.14
52W Range
52%
Rank17Top 4.2%
6.4
F-Score
Modified Piotroski Analysis
Based on 10-year fundamentals
Strong • 6.4 / 9 points
Scoring Range (0-9)
8-9: Excellent Value
6-7: Strong Fundamentals
4-5: Average Quality
0-3: Weak Performance
Data Period: 2016-2025

Financial Dashboard

Q4 2025 Data

Revenue

$1.09B+14.28%
4-Quarter Trend

EPS

$3.10+17.87%
4-Quarter Trend

FCF

$322.59M+46.49%
4-Quarter Trend

2025 Annual Earnings Highlights

Key Highlights

Total Revenue Growth Strong Total revenue reached $4.304B, up 10.4% compared to prior year; organic growth was 9.6%.
Operating Profit Surges 20.5% Income from operations grew 20.5% to $1.360B, driven by gross profit margin expansion and productivity.
CAG Recurring Revenue Up CAG recurring revenue increased 8.9% to $3.407B, supported by higher volumes and realized prices.
Cash Flow From Operations Cash provided by operating activities increased $252.8M to $1.182B for the year ended December 31, 2025.

Risk Factors

Intense Industry Competition Failure to execute strategy in highly competitive environment negatively impacts future growth and profitability outlook.
Supplier Dependence Risks Reliance on sole/single-source suppliers risks supply chain disruption, increased product costs, and potential customer loss.
Macroeconomic Vulnerability Demand sensitive to slow economic growth, inflation, and cautious consumer spending affecting patient visits and capital purchases.
LPD Segment Income Decline Livestock, Poultry, Dairy segment income dropped 51.3% to $3.229M due to higher product costs.

Outlook

AI Integration Strategy Focus Continued investment in AI integration across products and internal operations to drive efficiency and customer value.
CAG Growth Drivers Identified Success depends on increasing utilization of consumables and successful placement of new IDEXX inVue Dx Analyzer.
Managing Global Currency Risk Anticipate favorable impacts from foreign currency hedging activity, though actual results depend on exchange rates.
Projected Capital Expenditures Projected capital expenditures for 2026 estimated at approximately $180.0M for growth and software development.

Peer Comparison

Revenue (TTM)

COR stock ticker logoCOR
$325.78B
+7.4%
CAH stock ticker logoCAH
$244.49B
+10.1%
TAK stock ticker logoTAK
$30.01B
-2.0%

Gross Margin (Latest Quarter)

ARGX stock ticker logoARGX
89.3%
-53.8pp
EW stock ticker logoEW
78.3%
-2.7pp
ALNY stock ticker logoALNY
75.6%
+1.4pp

Key Metrics

Symbol
Market Cap
P/E (TTM)
ROE (TTM)
Debt to Assets
COR$68.60B42.1101.4%10.1%
BDX$57.83B25.96.9%35.6%
TAK$56.14B79.31.6%31.5%

Long-Term Trends

Last 4 Quarters
Revenue
Net Income
Operating Cash Flow
4Q Revenue CAGR
3.0%
Moderate Growth
4Q Net Income CAGR
0.8%
Profitability Slowly Improving
Cash Flow Stability
100%
Strong Cash Flow

Deep Research

Next earnings:Apr 29, 2026
|
EPS:-
|
Revenue:-
Financials
Earnings Calls
Reports
News
Income Statement
Balance Sheet
Cash Flow Statement
Ratios
% Chg.
Income Statement
LTM
No Data